A new treatment option for complex perianal fistulas in Crohn’s disease patients; development of darvadstrocel (allogeneic expanded adipose-derived mesenchymal stem cells) in Japan
Folia Pharmacologica Japonica · 2024
DOI: 10.1254/fpj.23046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Folia Pharmacologica Japonica, 2024. Verfasst von Takayoshi Yamaguchi. Beteiligte Einrichtung: Clinical Science, Therapeutic Area Strategy Unit, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited. Hauptthemen laut MEDLINE: Crohn Disease, Rectal Fistula, Mesenchymal Stem Cell Transplantation. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Crohn's disease (CD) is a chronic and relapsing inflammatory bowel disease affecting the entire gastrointestinal tract. The prevalence of CD among Japanese people is increasing. One of the most frequent complications of CD is perianal fistulas. People living with CD may experience complex perianal fistulas, which can cause intense pain, bleeding, swelling, infection, and anal discharge. Despite medical and surgical advancements, complex perianal fistulas in CD remain challenging for clinicians to treat. CD patients living with perianal fistulas reported a negative impact on many aspects of their quality of life. Darvadstrocel is a cell therapy product containing a suspension of allogeneic expanded adipose-derived mesenchymal stem cells. It has been approved in Europe and Japan for the treatment of complex perianal fistulas that have shown an inadequate response to at least one conventional or biologic therapy in adult patients with non-active/mildly active luminal CD. By exhibiting immunomodulatory and local anti-inflammatory effects at the site of inflammation, it offers a new treatment option for complex perianal fistulas in CD patients. In this manuscript, the characteristic of darvadstrocel, the summary of results from the pivotal phase 3 studies in Europe and Japan, and the development strategy in Japan were introduced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Clinical Science, Therapeutic Area Strategy Unit, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited.
Zitieren
APA
Yamaguchi, T. (2024). A new treatment option for complex perianal fistulas in Crohn’s disease patients; development of darvadstrocel (allogeneic expanded adipose-derived mesenchymal stem cells) in Japan. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.23046
Vancouver
Yamaguchi T. A new treatment option for complex perianal fistulas in Crohn’s disease patients; development of darvadstrocel (allogeneic expanded adipose-derived mesenchymal stem cells) in Japan. Folia Pharmacologica Japonica. 2024. doi:10.1254/fpj.23046
BibTeX
@article{Yamaguchi2024,
author = {Yamaguchi, Takayoshi},
title = {A new treatment option for complex perianal fistulas in Crohn’s disease patients; development of darvadstrocel (allogeneic expanded adipose-derived mesenchymal stem cells) in Japan},
journal = {Folia Pharmacologica Japonica},
year = {2024},
doi = {10.1254/fpj.23046}
}
EUVIMED